reviewed april 2026|next review october 2026|88 physicians psi has verified|27 published studies
CJC-1295
CJC-1295 is a modified GHRH (growth hormone-releasing hormone) analog with Phase I/II human pharmacokinetic data confirming sustained GH and IGF-1 elevation, available in two formulations: with DAC (Drug Affinity Complex) for weekly dosing and without DAC for daily use alongside ipamorelin.
Evidence landscape: 27 published studies
27 published items. 2 human studies and 21 animal studies. Confirmed pharmacokinetics with no outcomes data.
- 2 Human
- 21 Animal
- 4 Reviews
Not FDA-approved. The DAC variant is on the FDA Category 2 list, meaning licensed pharmacies cannot currently compound it. The non-DAC variant (mod GRF 1-29) regulatory status is under review.
Phase I/II pharmacokinetic data confirms 2-10 fold GH elevation and 1.5-3 fold IGF-1 elevation. Zero published outcomes data for body composition, sleep, or performance.
The most prescribed GH secretagogue combination in functional medicine pairs CJC-1295 with ipamorelin. No controlled trial has tested this combination for clinical outcomes.
PSI Assessment
The most prescribed growth hormone secretagogue combination in functional medicine pairs CJC-1295 with ipamorelin, two peptides that activate complementary GH release pathways. The pharmacological rationale is sound: CJC-1295 targets the GHRH receptor while ipamorelin targets the ghrelin receptor, and the two pathways produce synergistic GH amplification. The gap between clinical adoption and published evidence is one of the widest in the peptide space. No controlled trial has tested the combination for clinical outcomes.
The most prescribed GH secretagogue combination in functional medicine. Zero published outcomes data for the combination despite widespread clinical use.
The mechanism is GHRH receptor agonism. CJC-1295 is a modified GRF(1-29) peptide with four amino acid substitutions that prevent enzymatic degradation. Two versions exist: with DAC (Drug Affinity Complex), which binds albumin and extends the half-life to 6-8 days enabling weekly dosing, and without DAC (mod GRF 1-29), which has a short half-life and is typically injected alongside ipamorelin.
What the evidence supports
Phase I/II data confirms dose-dependent GH and IGF-1 elevation sustained for 6-8 days with the DAC formulation. The GHRH receptor mechanism is well-understood. The DAC modification successfully extends the half-life from approximately 30 minutes to 6-8 days. Pharmacokinetic data is published and consistent across studies.
What is not yet established
Whether the GH increase from CJC-1295 produces meaningful clinical outcomes beyond biomarker changes. No Phase III trials have been conducted. No long-term safety data exists. Whether the combination with ipamorelin is superior to either compound alone, despite being the most prescribed protocol in functional medicine.
Research Evidence
The findings below cover the confirmed pharmacokinetic data and the gap between adoption and evidence.
Evidence by condition
Evidence dimensions across CJC-1295 indications. GH stimulation has pharmacokinetic confirmation. All clinical outcome indications lack controlled human data.
| Condition | Mechanism | Animal evidence | Human evidence | Replication |
|---|---|---|---|---|
| GH Stimulation | ||||
| Body Composition | ||||
| Sleep Quality | ||||
| Anti-Aging |
Phase I/II data demonstrates dose-dependent GH elevation (2-10 fold) and IGF-1 elevation (1.5-3 fold) sustained for more than 6 days with the DAC formulation. The pharmacokinetic profile is published and consistent.
Hormone elevation is a biomarker, not a clinical outcome. Whether raising GH with CJC-1295 improves any measurable health endpoint has not been tested in a controlled trial.
The DAC conjugation binds serum albumin, extending the half-life from approximately 30 minutes to 6-8 days. This enables weekly dosing versus the daily injections required with the non-DAC version.
The pharmacokinetic achievement is notable. However, the sustained GH elevation from DAC raises theoretical concerns about chronic IGF-1 elevation that have not been evaluated in long-term safety studies.
Zero published clinical outcomes data exists for body composition, sleep quality, recovery, or performance from any controlled CJC-1295 trial. The CJC-1295 plus ipamorelin combination, the most common clinical protocol, has never been tested in a controlled comparison study.
The gap between clinical adoption and published evidence is one of the widest in the peptide space. The combination is pharmacologically rational (complementary receptor pathways) but clinically unvalidated.
2 Human|21 Animal|4 Reviews
View all 27 indexed studiesHow CJC-1295 Works
CJC-1295 is a modified GRF(1-29) peptide with amino acid substitutions at positions 2, 8, 15, and 27 to prevent DPP-IV (dipeptidyl peptidase-IV) enzymatic degradation. It binds GHRH receptors on anterior pituitary somatotrophs, activating adenylyl cyclase via Gs protein coupling to stimulate pulsatile GH secretion.
Think of CJC-1295 as pressing the button that tells your body to make more growth hormone, rather than injecting growth hormone directly. The DAC version keeps that button pressed for up to a week per dose.
For a more detailed view of the biology, here is what researchers have observed at the molecular level.
CJC-1295 mimics the body's natural growth hormone-releasing hormone (GHRH), telling the pituitary gland to produce and release growth hormone. Unlike exogenous GH injection, it preserves the body's natural pulsatile GH release pattern. The DAC (Drug Affinity Complex) version binds to albumin in the blood, extending its duration of action to nearly a week per dose. This preservation of physiological pulsatility is considered an advantage over direct GH administration, which bypasses the pituitary entirely.
What is CJC-1295 being studied for?
Researchers are studying CJC-1295 across several health conditions. Each condition below is labeled with the strength of evidence that exists for that specific use, not for CJC-1295 overall. This means a compound can have human studies for one condition but only animal data for another.
GH Stimulation
·Animal StudiesPhase I/II data confirms dose-dependent GH and IGF-1 elevation. The DAC formulation provides sustained elevation over 6-8 days from a single injection.
Limitations: Hormone elevation is a biomarker, not a clinical outcome. Whether this translates to meaningful body composition, performance, or health benefits has not been demonstrated in controlled trials.
Body Composition
·Animal StudiesExpected effects (reduced fat mass, increased lean mass) are inferred from GH physiology rather than direct CJC-1295 outcome data. No controlled human trials have measured body composition as a primary endpoint.
Limitations: Complete absence of published human body composition data with CJC-1295.
Sleep Quality
·PreclinicalGH secretion is physiologically linked to deep sleep. Community reports suggest improved sleep, but no controlled studies have evaluated CJC-1295 for sleep outcomes.
Limitations: Purely theoretical extrapolation from GH physiology. No CJC-1295-specific sleep data exists.
Anti-Aging
·PreclinicalThe hypothesis that restoring GH levels may slow age-related decline is biologically plausible but untested with CJC-1295. The GH-aging relationship is complex and not straightforwardly beneficial.
Limitations: No longevity data exists. Elevated IGF-1 has been associated with both positive and negative outcomes in aging populations.
Safety and Regulatory Status
FDA Status: Not FDA-approved. The DAC variant is on the FDA Category 2 list, meaning licensed pharmacies cannot currently compound it. The non-DAC variant (mod GRF 1-29) regulatory status is under review.
Availability: CJC-1295 without DAC is available through specialty pharmacies where a licensed pharmacist prepares a medicine from ingredients for an individual patient. The DAC variant has restricted availability.
Class context: Modified GHRH analog. Tesamorelin is the only GHRH analog with current FDA approval. Sermorelin was previously FDA-approved (voluntarily withdrawn).
Generally well tolerated in published human studies, with injection site reactions and flushing as the most common side effects. One death was reported in a clinical trial participant, though causality was not established. Long-term effects of sustained GH/IGF-1 elevation are a theoretical concern.
Peptide Structure
Technical molecular data for researchers and clinicians.
Questions and Comparisons
Questions the evidence raises for a CJC-1295 discussion.
Comparison and Related Research
CJC-1295 is most often compared with other GH secretagogues and GHRH analogs. The comparisons below outline how each differs in evidence depth, mechanism, and regulatory status.
Head-to-head comparisons
Full research comparisons covering CJC-1295 and another peptide side by side.
CJC-1295 vs Ipamorelin
Evidence-based comparison of CJC-1295 and ipamorelin for growth hormone stimulation. Mechanism differences, evidence levels, study findings, and safety profiles analyzed.
View full comparisonCJC-1295 vs Sermorelin
Research-based comparison of sermorelin and CJC-1295 for growth hormone stimulation. Mechanism, pharmacokinetics, evidence levels, and clinical data compared side-by-side.
View full comparisonCJC-1295 vs MK-677
Three-way comparison of MK-677, ipamorelin, and CJC-1295 for growth hormone research. Mechanisms, evidence levels, oral vs. injectable delivery, and safety profiles analyzed.
View full comparisonCJC-1295 vs MK-677 (Ibutamoren)
MK-677 is oral with more human data. CJC-1295 is injectable with fewer side effects. Evidence-graded comparison of two GH optimization approaches.
View full comparisonCJC-1295 vs BPC-157
BPC-157 repairs tissue. CJC-1295 elevates growth hormone. Evidence-graded comparison of two peptides that serve fundamentally different purposes.
View full comparisonCJC-1295 vs Tesamorelin
Tesamorelin is FDA-approved for HIV lipodystrophy. CJC-1295 is a research compound used broadly. Same receptor, different regulatory status. Evidence compared.
View full comparisonCJC-1295 vs MK-677 (Ibutamoren)
The most popular injectable GH stack vs the oral option. Better side effects vs easier dosing. Evidence-graded comparison.
View full comparisonRelated compounds
Frequently Asked Questions
References
Each citation links to the original study on PubMed, the U.S. National Library of Medicine database.
- 1.Phase II trial demonstrating that a single injection of CJC-1295 produced sustained elevation of growth hormone and IGF-1 levels in healthy adults for up to two weeks. This prolonged duration of action - far longer than native GHRH - was the key finding that differentiated CJC-1295 from earlier secretagogues.Teichman SL et al., 2006 in J Clin Endocrinol Metab. View on PubMed
- 2.Animal study showing that once-daily CJC-1295 restored normal growth in mice genetically lacking their own GHRH signaling. The results confirmed that the compound's extended half-life translated into meaningful biological activity with infrequent dosing.Alba M et al., 2006 in Am J Physiol Endocrinol Metab. View on PubMed
- 3.Human study showing that the body's natural pulsatile pattern of growth hormone release was preserved even during sustained CJC-1295 stimulation. This was clinically relevant because continuous (non-pulsatile) GH elevation can reduce receptor sensitivity over time.Ionescu M & Frohman LA, 2006 in J Clin Endocrinol Metab. View on PubMed
- 4.The foundational paper describing the Drug Affinity Complex (DAC) technology that gives CJC-1295 its long duration of action. The bioconjugate binds to circulating albumin after injection, shielding the peptide from rapid breakdown and extending its half-life from minutes to days.Jette L et al., 2005 in Endocrinology. View on PubMed
Medical Disclaimer
This content is for educational and informational purposes only and does not constitute medical advice. The information presented reflects published research as indexed by PSI and should not be used to make treatment decisions. Always consult a qualified healthcare provider before starting, stopping, or modifying any treatment.